0O2.F Sagimet Biosciences Inc.

Healthcare Biotechnology Frankfurt Exchange
9.25 EUR
Close of Nov 11, 2026
3.86 9.66
Market cap
EUR 651M
P/E
-
P/B
2.66x
ROE
-19.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0O2.F undervalued?

Graham number

The Graham number of Sagimet Biosciences Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Sagimet Biosciences Inc. fundamental analysis

No fundamental analysis for Sagimet Biosciences Inc. yet.

Sagimet Biosciences Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Sagimet Biosciences Inc.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also deve…

Full company profile